<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199339</url>
  </required_header>
  <id_info>
    <org_study_id>TBA-7371-CL001</org_study_id>
    <nct_id>NCT03199339</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371</brief_title>
  <official_title>Phase 1, Partially-Blind, Placebo Controlled Randomized, Combined SAD With Food Effect Cohort and MAD and DDI Study to Evaluate Safety, Tolerability, PK and PK Interaction Between TBA-7371 With Midazolam and Bupropion in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety and tolerability of single and&#xD;
      multiple doses of TBA-7371 in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three - part, partially-blinded, placebo controlled, combined single ascending dose with a&#xD;
      food effect cohort and multiple ascending dose and a drug-drug interaction study to be&#xD;
      conducted in one study center in the United States.&#xD;
&#xD;
      Part 1 has a single ascending dose (SAD) design with up to 5 planned dose levels. Based on&#xD;
      the interim PK for the dose escalation decisions, a dose cohort will be selected to return&#xD;
      for an additional dose after a high calorie, high fat meal.&#xD;
&#xD;
      Safety will be assessed throughout the study; serial ECGs and serial blood samples will be&#xD;
      collected for the safety and PK assessment of TBA-7371. Dose escalation to the next cohort&#xD;
      (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal&#xD;
      Investigator, has determined that adequate safety, tolerability and PK from the previous&#xD;
      cohort has been demonstrated to permit proceeding to the next cohort.&#xD;
&#xD;
      Interim PK analyses will be performed for the dose escalation decisions, to select the&#xD;
      intermediate dose for the food effect cohort, and to reconsider the sampling time points as&#xD;
      the study progresses. All samples will be sent for analysis and the bioanalytical lab will be&#xD;
      unblinded and only run the analysis on active treatment subjects. Data from the analysis used&#xD;
      for the escalation meetings will only include active treatment subjects, and will be blinded&#xD;
      by subject.&#xD;
&#xD;
      Subjects will be housed in the WCT clinic from at least 24 hours prior (from Day -2), until&#xD;
      48 hours after dosing. Subjects will return for subsequent follow up safety and PK&#xD;
      assessments on Day 4 and will be contacted via a phone call for follow-up questioning about&#xD;
      adverse events 7 days later (Study Day 11). One cohort will return after a washout of at&#xD;
      least 7 days or five half-lives (whichever is longer) of their fasting dose to receive the&#xD;
      same intermediate dose (TBD mg) under fed conditions.&#xD;
&#xD;
      Part 2 has a multiple ascending dose design. The dose cohorts for Part 2 will be determined&#xD;
      based on model predictions to determine the steady-state Cmax exposure, and safety from Part&#xD;
      1.&#xD;
&#xD;
      In this multiple ascending dose part, each subject will be administered TBA-7371 or matching&#xD;
      placebo for 14 days with corresponding PK measurements. Three dose cohorts are planned. After&#xD;
      each dose cohort, the Sponsor and Investigator will review the PK and safety data before&#xD;
      proceeding to the next dose level.&#xD;
&#xD;
      Part 3 has an open-label, multi-dose, fixed sequence drug-drug interaction study design. The&#xD;
      dose of TBA-7371 to be studied will dependent on the interim PK analyses and safety from Part&#xD;
      2.&#xD;
&#xD;
      In this DDI part, each subject (n=14) will be administered midazolam (2 mg suspension) and&#xD;
      bupropion (150 mg, tablet) together on Day 1, followed by a 7-day washout, followed by&#xD;
      administration of TBA-7371 on Days 8 through 21, followed by administration of midazolam, and&#xD;
      bupropion on Day 22. PK will be assessed for midazolam on Days 1 and 22, bupropion on Days 1&#xD;
      - 5 and 22 - 26, and TBA-7371 on Days 8-21.&#xD;
&#xD;
      At the end of Part 1 and at the end of Part 2, pharmacokinetic and safety data along with&#xD;
      reasons for doses for the next part (Part 2 and Part 3, respectively) will be sent to the&#xD;
      Food and Drug Administration (FDA) for review and approval. The study will not proceed to&#xD;
      Part 2 or Part 3 until the FDA provides approval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">July 8, 2018</completion_date>
  <primary_completion_date type="Actual">July 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Part 1 and Part 2 participants will be masked, Part 3 participants will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects by number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-7371 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single and multiple doses of TBA-7371 AUC(0-t)</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through AUC(0-t). AUC = Area under the curve, t = determined time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single and multiple doses of TBA-7371 using Cmax</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through Cmax. , Cmax = maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of single and multiple doses of TBA-7371 using Tmax</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through Tmax, Tmax = Time of the maximum drug concentration (obtained without interpolation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate and extent of absorption of a single oral dose of TBA-7371 using AUC, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like AUC; AUC = Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate and extent of absorption of a single oral dose of TBA-7371 using Cmax, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like Cmax; Cmax = maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the rate and extent of absorption of a single oral dose of TBA-7371 using Tmax, when administered after a high-calorie, high-fat meal versus when it's administered fasting in healthy adult subjects</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like Tmax; Tmax = Time of the maximum drug concentration (obtained without interpolation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using AUC</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like AUC; AUC = Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using Cmax</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like Cmax; Cmax = maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of multiple-dose administration of TBA-7371 on the pharmacokinetics of midazolam and bupropion using Tmax</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>This will be measured through PK parameters like Tmax; Tmax = Time of the maximum drug concentration (obtained without interpolation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the combination of TBA7371 with midazolam and bupropion by the number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Days 0-28 (depending on dosing schedule)</time_frame>
    <description>The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-7371 and placebo</description>
  </secondary_outcome>
  <number_of_arms>19</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 1 First Dose - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 2, 100 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 1 First Dose - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 1, 100 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 1 Second Dose - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 4, 100 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 1 Second Dose -Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 1, 100 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 2 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N= 6, 250 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 250 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 3 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 500 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 3 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 500 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 4 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 1000 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 4 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 1000 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 5 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 6, 1500 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Cohort 5 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 2, 1500 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 1 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 9, 100 mg TBA-7371 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 3, 100 mg TBA-7371 or matching placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 2 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 9, 200 mg TBA-7371 or matching placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 3, 200 mg TBA-7371 or matching placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 3 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 9, 400 mg TBA-7371 or matching placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Part 2 Cohort 3 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 3, 400 mg TBA-7371 or matching placebo for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDI Part 3 Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBA-7371</intervention_name>
    <description>The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.</description>
    <arm_group_label>DDI Part 3 Cohort 1</arm_group_label>
    <arm_group_label>MAD Part 2 Cohort 1 - Active</arm_group_label>
    <arm_group_label>MAD Part 2 Cohort 2 - Active</arm_group_label>
    <arm_group_label>MAD Part 2 Cohort 3 - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 1 First Dose - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 1 Second Dose - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 2 - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 3 - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 4 - Active</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 5 - Active</arm_group_label>
    <other_name>Midazolam (oral syrup)</other_name>
    <other_name>Bupropion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.</description>
    <arm_group_label>MAD Part 2 Cohort 1 - Placebo</arm_group_label>
    <arm_group_label>MAD Part 2 Cohort 2 - Placebo</arm_group_label>
    <arm_group_label>MAD Part 2 Cohort 3 - Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 1 First Dose - Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 1 Second Dose -Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 2 - Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 3 - Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 4 - Placebo</arm_group_label>
    <arm_group_label>SAD Part 1 Cohort 5 - Placebo</arm_group_label>
    <other_name>Matching Placebo for TBA-7371</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following inclusion criteria and none of the exclusion&#xD;
        criteria to be eligible for participation in the study, unless otherwise specified.&#xD;
&#xD;
          1. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age&#xD;
             (inclusive) at the time of screening.&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50.0&#xD;
             kg.&#xD;
&#xD;
          3. Medically healthy with no clinically significant screening results (e.g., laboratory&#xD;
             profiles, medical histories, vital signs, ECGs, physical examination) as deemed by the&#xD;
             Investigator.&#xD;
&#xD;
          4. No use of tobacco or nicotine containing products (including smoking cessation&#xD;
             products), for a minimum of 6 months prior to dosing.&#xD;
&#xD;
          5. Females of non-childbearing potential, having undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to dosing:&#xD;
&#xD;
             i. Hysteroscopic sterilization ii. Bilateral tubal ligation or bilateral salpingectomy&#xD;
             iii. Hysterectomy iv. Bilateral oophorectomy v. or be postmenopausal with amenorrhea&#xD;
             for at least 1 year prior to the first dose with serum follicle stimulating hormone&#xD;
             (FSH) levels consistent with postmenopausal status at screening.&#xD;
&#xD;
          6. Non-vasectomized males (or males vasectomized less than 120 days prior to study&#xD;
             start), must agree to the following during study participation and for 90 days&#xD;
             following the last administration of study drug:&#xD;
&#xD;
               1. use a condom with spermicide while engaging in sexual activity or be sexually&#xD;
                  abstinent&#xD;
&#xD;
               2. not donate sperm during this time. In the event the sexual partner is surgically&#xD;
                  sterile, use of a condom with spermicide is not necessary. None of the&#xD;
                  restrictions listed above are required for vasectomized males whose procedure was&#xD;
                  performed more than 120 days prior to study start.&#xD;
&#xD;
          7. Willing to answer inclusion and exclusion criteria questionnaire at check-in.&#xD;
&#xD;
          8. Subject understands study procedures and provides written informed consent for the&#xD;
             trial.&#xD;
&#xD;
          9. Be able to comply with the protocol and the assessments therein, including all&#xD;
             restrictions.&#xD;
&#xD;
         10. Is willing and able to remain in the study unit for the entire duration of the&#xD;
             assigned confinement period and return for outpatient visits.&#xD;
&#xD;
         11. If enrolled in Part 1 and assigned to the fasted/fed cohort, is willing and able to&#xD;
             consume the entire high-calorie, high-fat breakfast meal in the timeframe required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from the study if there is evidence of any of the following&#xD;
        criteria at screening or check-in, as appropriate.&#xD;
&#xD;
          1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             or psychiatric disease as determined by the Investigator to be clinically relevant.&#xD;
&#xD;
          2. History of any illness that, in the opinion of the Investigator, might confound the&#xD;
             results of the study or poses an additional risk to the subject by their participation&#xD;
             in the study.&#xD;
&#xD;
          3. Surgery within the past 90 days prior to dosing as determined by the Investigator to&#xD;
             be clinically relevant, or any history of cholecystectomy.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years as determined&#xD;
             by the Investigator to be clinically relevant.&#xD;
&#xD;
          5. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          6. Positive results for the urine drug/alcohol screen at screening or check-in.&#xD;
&#xD;
          7. Positive urine cotinine at screening or check in.&#xD;
&#xD;
          8. Serum magnesium potassium, or calcium laboratory values outside of the normal range at&#xD;
             screening.&#xD;
&#xD;
          9. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B&#xD;
             Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).&#xD;
&#xD;
         10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             screening, Day -2 (check-in), Day -1, or predose. Out-of-range vital signs may be&#xD;
             repeated once for confirmation.&#xD;
&#xD;
         11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening, Day -2&#xD;
             (check-in), Day -1, or predose. Out-of-range vital signs may be repeated once for&#xD;
             confirmation.&#xD;
&#xD;
         12. Any electrocardiogram abnormality at Screening (as deemed by decision of the&#xD;
             Investigator and the Sponsor's Medical Monitor).&#xD;
&#xD;
             NOTE: The following can be considered not clinically significant without consulting&#xD;
             the Sponsor's Medical Monitor:&#xD;
&#xD;
             i. Mild first degree A-V block (P-R interval &lt;0.23 sec) ii. Right or left axis&#xD;
             deviation iii. Incomplete right bundle branch block iv. Isolated left anterior&#xD;
             fascicular block (left anterior hemiblock) in younger athletic subjects&#xD;
&#xD;
         13. QTcF interval &gt;450 msec for males or &gt;470 msec for females at screening, Day -2, Day&#xD;
             -1, or Day 1 (pre-dose), or history of prolonged QT syndrome.&#xD;
&#xD;
         14. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a&#xD;
             condition that could be causative of sudden death (such as known coronary artery&#xD;
             disease, congestive heart failure or terminal cancer).&#xD;
&#xD;
         15. History of one or any combination of, the following:&#xD;
&#xD;
             i. Seizures or seizure disorders ii. Brain surgery. iii. History of head injury in the&#xD;
             last five years iv. Any serious disorder of the CNS or related neurological system,&#xD;
             particularly one that may lower the seizure threshold.&#xD;
&#xD;
             v. History of seizures&#xD;
&#xD;
         16. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
         17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,&#xD;
             within the 7 days prior to dosing, except acetaminophen. Up to 3 grams per day of&#xD;
             acetaminophen is allowed at the discretion of the Investigator prior to dosing.&#xD;
&#xD;
         18. Use of any drugs or substances known to be significant inhibitors of Cytochrome P450&#xD;
             (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein (P-gp)&#xD;
             and/or Organic anion transporting polypeptides (OATP) within 14 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
         19. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp,&#xD;
             including St. John's Wort, within 30 days prior to the first dose of study drug.&#xD;
&#xD;
         20. Use of any drugs or substance known to lower the seizure threshold.&#xD;
&#xD;
         21. Blood donation or significant blood loss within 56 days prior to dosing.&#xD;
&#xD;
         22. Plasma donation within 7 days prior to dosing.&#xD;
&#xD;
         23. Participation in another clinical trial within 28 days prior to dosing. Consumption of&#xD;
             foods and beverages containing the following substances will be prohibited&#xD;
&#xD;
         24. Has been on a significantly abnormal diet during the 4 weeks preceding the first dose&#xD;
             of study medication.&#xD;
&#xD;
         25. Unwilling to remove any artificial nails (e.g. acrylic, gel) or fingernail polish and&#xD;
             not use such products for the duration of the study.&#xD;
&#xD;
         26. Is colorblind (assessed using the Ishihara Color Vision Test)&#xD;
&#xD;
             Additionally, the following exclusion applies only to subjects in Part 1, the SAD&#xD;
             study:&#xD;
&#xD;
         27. Is lactose intolerant.&#xD;
&#xD;
             Additionally, the following exclusion applies only to subjects in Part 1 and 2, the&#xD;
             SAD and MAD studies:&#xD;
&#xD;
         28. History or presence of allergic or adverse response to Listerine breath strips or&#xD;
             aspartame.&#xD;
&#xD;
             Additionally, the following exclusions apply only to subjects in Part 3, the DDI&#xD;
             study:&#xD;
&#xD;
         29. History or presence of allergic or adverse response to midazolam, bupropion, or&#xD;
             related drugs.&#xD;
&#xD;
         30. History of presence of acute narrow-angle or untreated open-angle glaucoma&#xD;
&#xD;
         31. Current or prior diagnosis of bulimia or anorexia nervosa&#xD;
&#xD;
         32. Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or anti-epileptic&#xD;
             drugs within 14 days prior to the first dose of study treatment&#xD;
&#xD;
         33. Discontinued the use of monoamine oxidase inhibitors (MAOs) within 14 days prior to&#xD;
             the first dose of study treatment&#xD;
&#xD;
         34. History or presence of suicidal ideation or suicidal behavior as assessed by the&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS, Baseline/Screening Version) at the&#xD;
             Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Del Parigi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Global Alliance for TB Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>TBA7371</keyword>
  <keyword>TBA-7371</keyword>
  <keyword>TB Alliance</keyword>
  <keyword>TB</keyword>
  <keyword>Pulmonary Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

